2026-01-17
4 分钟Hey listeners, your money briefing is on a break,
but it will be back with more personal finance information for you in the future.
Until then, here's the news moving markets this week.
That was the theme for Markets This Week.
On Sunday night, news broke that Federal Reserve Chair Jerome Powell is being investigated by U.S.
prosecutors over his testimony about the central bank's building renovation project.
In a video statement, Powell, who is usually quite restrained,
called the investigation a pretext as part of President Trump's campaign to pressure the Fed to lower interest rates and in the independence of the central bank.
Investors, concerned that a lack of Fed independence could lead to runaway inflation,
have been closely watching the Powell situation.
Meanwhile, banks kicked off earning season with a mixed bag of results.
JP Morgan disappointed investors with lower than expected investment banking revenue,
but Goldman Sachs and Morgan Stanley posted strong quarters.
At the index level, stocks inched lower for the week.
The S&P 500 ended down 0.4%, just shy of a record high.
The dial fell 0.3% while the NASDAQ composite was 0.7% lower.
Novo Nordisk's shares jumped in the US on Friday after a string of positive news about its flagship weight loss drug,
Wagovi.
The UK's health regulator approved a significantly higher dose of the drug for patients with a body mass index of at least 30.
The Danish drugmaker is awaiting regulatory approvals for the same size dose in the US and the EU.